Ceftaroline

Abstract

Community-acquired pneumonia (CAP) is one of the leading causes of admission to emergency departments. Cef-taroline is a fifth-generation cephalosporin with a potent In vitro activity against Streptococcus pneumoniae, Haemophi-lus influenzae and Staphylococcus aureus, the three most important pathogens causing CAP. Three randomized and double-blind clinical trials compared the efficacy of ceftaro-line versus ceftriaxone in patients with CAP and the results of each trial and a meta-analysis, concluded the superiority of ceftaroline in terms of clinical success. In particular, the ma-jor difference was observed among patients with CAP caused by S. aureus. Accordingly, ceftaroline has been included as a first-line option in the recent clinical guidelines for the management of CAP.